Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | NOX1 | Q9Y5S8 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | SNCA | P37840 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYBB | P04839 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.50 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11389792 | 0.89 | L3MBTL1 (0.62) | L3MBTL1HPGDMAPTNOX1GAA | |
| SCHEMBL23094972 | 0.88 | HPGD (0.55) | L3MBTL1HPGDMAPTNOX1GAA | |
| SCHEMBL11390726 | 0.87 | L3MBTL1 (0.60) | L3MBTL1HPGDMAPTNOX1GAA | |
| SCHEMBL11396667 | 0.87 | L3MBTL1 (0.60) | L3MBTL1HPGDMAPTNOX1GAA | |
| SCHEMBL4670438 | 0.86 | HPGD (0.70) | L3MBTL1HPGDMAPTNOX1GAA | |
| SCHEMBL11396917 | 0.84 | TP53 (0.61) | L3MBTL1HPGDMAPTNOX1GAA | |
| SCHEMBL29441686 | 0.83 | HPGD (0.51) | L3MBTL1HPGDMAPTNOX1GAA | |
| SCHEMBL17085845 | 0.83 | HPGD (0.51) | L3MBTL1HPGDMAPTNOX1GAA | |
| SCHEMBL5121603 | 0.83 | NOX1 (0.60) | L3MBTL1MAPTNOX1GAAMEN1 | |
| SCHEMBL11390619 | 0.81 | L3MBTL1 (0.49) | L3MBTL1HPGDMAPTNOX1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4263207-A | ANTIALLERGENS | MERCK & CO., INC. (US) | 1981-04-21 | — | — | US | claimed |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| EP-3305784-B1 | HAPTENS OF QUETIAPINE FOR USE IN IMMUNOASSAYS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3305784-B1 | HAPTENS OF QUETIAPINE FOR USE IN IMMUNOASSAYS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3663317-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | Janssen Pharmaceutica NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| EP-3385284-B1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-26 | — | — | EP | disclosed |
| EP-3385284-B1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-26 | — | — | EP | disclosed |
| US-20200040107-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-06 | — | — | US | disclosed |
| US-20200040107-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-06 | — | — | US | disclosed |
| EP-2888286-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | Ortho-Clinical Diagnostics Inc (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140221616-A1 | HAPTENS OF QUETIAPINE | ORTHO-CLINICAL DIAGNOSTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221616-A1 | HAPTENS OF QUETIAPINE | ORTHO-CLINICAL DIAGNOSTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221616-A1 | HAPTENS OF QUETIAPINE | ORTHO-CLINICAL DIAGNOSTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140057305-A1 | Antibodies to Quetiapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057305-A1 | Antibodies to Quetiapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057305-A1 | Antibodies to Quetiapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031665-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | ORTHO-CLINICAL DIAGNOSTICS, INC (US) | 2014-02-27 | — | — | WO | disclosed |
| US-5607929-A | Antiviral dibenzothiazepinone derivatives | GLAXO WELLCOME INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-4263207-A | ANTIALLERGENS | MERCK & CO., INC. (US) | 1981-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057305-A1 | Antibodies to Quetiapine Haptens and Use Thereof | HTR4, HTR3C, SLC6A4 | L3MBTL1 2785/4885HPGD 2037/4885MAPT 1638/4885 |
| US-20200040107-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, SLC6A4 | L3MBTL1 2785/4885HPGD 2037/4885MAPT 1638/4885 |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, SLC6A4 | L3MBTL1 2785/4885HPGD 2037/4885MAPT 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.